Dashboard

TSXV: ATE CAD ${{ stocks['ATE.V'].LastPrice }}
Last updated: {{ getStockDate(stocks['ATE.V']) }} ET
OTCQB: ATBPD USD ${{ stocks['ATBPD'].LastPrice }}
Last updated: {{ getStockDate(stocks['ATBPD']) }} ET
CAD ${{ getMCap(stocks['ATE.V']) }}M
MARKET CAP
CAD ${{ stocks['ATE.V'].YearHigh }}/${{ stocks['ATE.V'].YearLow }}
52-WEEK HIGH/LOW
{{ stocks['ATE.V'].AverageDailyVolume3Month }}
AVG. DAILY TRADING VOLUME
18%
INSIDER OWNERSHIP

Investor Presentation

Learn how Antibe is aiming to change the game in pain and inflammation medicine. Delve into our market opportunity, drug pipeline, and the science that underlies our drug platform.

Download Investor Presentation

Last updated: September 2019

Quarterly & Annual Reports

June 30, 2019

Q1/F20: Management’s Discussion & Analysis
June 30, 2019

Q1/F20: Quarterly Financial Statements
March 31, 2019

FY2019 Annual Information Form
March 31, 2019

FY2019 Management’s Discussion & Analysis
View financialsRegulatory Filings

Events & Conferences

January 17 - 19, 2020

AlphaNorth Capital Investment Conference

Nassau, Bahamas
January 13 - 15, 2020

Biotech Showcase

San Francisco, Callifornia
December 15 - 17, 2019

Pharmacology 2019

Edinburgh, Scotland
December 2 - 3, 2019

2nd Int’l Symposium on Pharmacology and Medicinal Chemistry

Rio de Janeiro, Brazil
See all events

Recent News

August 27, 2019

Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results
August 13, 2019

Antibe Announces Closing of Public Offering
Read all news

INVESTOR CONTACT

Christina Cameron
VP Investor Relations
christina@antibethera.com

Contact us